UPLC-QTOF/MS-Based Lipidomic Profiling of Liver Qi-Stagnation and Spleen-Deficiency Syndrome in Patients with Hyperlipidemia
Table 3
Identification results of varying ions and their change trend of hyperlipidemia and healthy volunteers.
NO
Retention Time
Mass
Group 1 Content
Group 2 Content
Factor of Change
VIPvalue
Change Trend
Identified potential Biomarker
Lipid Class
Ion
1
8.03
758.5651
4.7339±1.869
0.61515±0.6942
7.7
4.76901
↑
PE(22:2/15:0)
Glycerophospholipid
M+H
2
14.1
758.5656
24.4239±7.3675
16.0367±4.1211
1.5
19.6218
↑
PC(16:0/18:2)
Glycerophospholipid
M+H
3
15.4
769.5915
2.8041±0.8225
2.3896±0.8705
1.2
7.40167
↑
PG(18:3/18:2)
Glycerophospholipid
M+H
4
16.15
540.4826
0.2268±0.0674
0.1447±0.0368
1.6
4.95507
↑
Cer(d18:0/16:0)
Sphingomyelin
M+H
5
18.05
760.5777
24.6892±1.4525
8.4016±1.6207
2.9
16.1507
↑
PE(22:1/15:0)
Glycerophospholipid
M+H
6
14.32
832.6021
21.9211±6.4255
13.9741±3.9031
1.6
4.2825
↑
PE(15:0/24:1)
Glycerophospholipid
M+FA-H
7
14.37
804.5628
44.7529±12.4215
25.7829±2.6471
1.7
2.48245
↑
PC(22:6/16:0)
Glycerophospholipid
M+FA-H
Group 1: hyperlipidemia. Group 2: healthy volunteers.↑ indicated the concentrations compared to the other group are increasing. ↓ indicated the concentrations compared to the other group are reducing. P<0.05 and P<0.01. PE: phosphatidylethanolamine; PC: phosphatidylcholine; PG: phosphatidylglycerol; Cer: ceramide.
